Blocking the IL‑6 pathway to treat immune checkpoint inhibitor‑induced inflammatory arthritis (Review).

IF 3.5 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Molecular medicine reports Pub Date : 2025-09-01 Epub Date: 2025-07-11 DOI:10.3892/mmr.2025.13615

Liwen Zhao, Chuting Feng, Yong-Jing Gao, Tianzhen He

引用次数: 0

Abstract

The incorporation of immune checkpoint inhibitors (ICIs) into cancer treatment has revolutionized oncology, providing marked advantages in managing various types of cancer. Nevertheless, the increasing use of ICIs has led to the emergence of immune‑related side effects, including autoimmune diseases such as inflammatory arthritis. IL‑6 signaling is crucial in the development of inflammatory arthritis and is linked to both the benefits and adverse effects of ICIs. The present review summarizes the latest progress in the IL‑6 pathway in inflammatory arthritis and discusses the therapeutic potential of IL‑6 pathway inhibitors for ICI‑induced inflammatory arthritis.

Abstract Image

查看原文本刊更多论文

阻断IL - 6通路治疗免疫检查点抑制剂诱导的炎性关节炎（综述）

将免疫检查点抑制剂（ICIs）纳入癌症治疗已经彻底改变了肿瘤学，在治疗各种类型的癌症方面提供了显著的优势。然而，ICIs使用的增加导致免疫相关副作用的出现，包括炎症性关节炎等自身免疫性疾病。IL - 6信号在炎症性关节炎的发展中至关重要，并与ICIs的益处和不良反应有关。本文综述了IL - 6通路在炎性关节炎中的最新进展，并讨论了IL - 6通路抑制剂对ICI诱导的炎性关节炎的治疗潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular medicine reports 医学-病理学

CiteScore

7.60

自引率

0.00%

发文量

321

审稿时长

1.5 months

期刊介绍： Molecular Medicine Reports is a monthly, peer-reviewed journal available in print and online, that includes studies devoted to molecular medicine, underscoring aspects including pharmacology, pathology, genetics, neurosciences, infectious diseases, molecular cardiology and molecular surgery. In vitro and in vivo studies of experimental model systems pertaining to the mechanisms of a variety of diseases offer researchers the necessary tools and knowledge with which to aid the diagnosis and treatment of human diseases.